These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 37199884)
1. Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study. Kivitz A; Wells AF; Vargas JI; Baraf HSB; Rischmueller M; Klaff J; Khan N; Li Y; Carter K; Friedman A; Durez P Rheumatol Ther; 2023 Aug; 10(4):901-915. PubMed ID: 37199884 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study. Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM Rheumatol Ther; 2024 Jul; ():. PubMed ID: 39031276 [TBL] [Abstract][Full Text] [Related]
3. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND. van Vollenhoven RF; Hall S; Wells AF; Meerwein S; Song Y; Tanjinatus O; Fleischmann R RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053948 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577 [TBL] [Abstract][Full Text] [Related]
5. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Mueller RB; Schulze-Koops H; Furst DE; Cohen SB; Kwok K; Wang L; Killeen T; von Kempis J Clin Rheumatol; 2022 Apr; 41(4):1045-1055. PubMed ID: 34973077 [TBL] [Abstract][Full Text] [Related]
6. Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Fleischmann R; Blanco R; Van den Bosch F; Bessette L; Song Y; Penn SK; McDearmon-Blondell E; Khan N; Chan K; Mysler E Rheumatol Ther; 2024 Jun; 11(3):599-615. PubMed ID: 38498140 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540 [TBL] [Abstract][Full Text] [Related]
8. Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study. Bessette L; Chan J; Chow A; Lisnevskaia L; Richard N; Fournier PA; Liazoghli D; Girard T; Haaland D Rheumatol Ther; 2024 Jun; 11(3):563-582. PubMed ID: 38467912 [TBL] [Abstract][Full Text] [Related]
9. Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry. Baker JF; Zueger P; Ali M; Bennett D; Yu M; Munoz Maldonado Y; McLean RR Rheumatol Ther; 2024 Apr; 11(2):363-380. PubMed ID: 38345715 [TBL] [Abstract][Full Text] [Related]
10. Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). Burmester GR; Van den Bosch F; Tesser J; Shmagel A; Liu Y; Khan N; Camp HS; Kivitz A J Rheumatol; 2024 Jul; 51(7):663-672. PubMed ID: 38621793 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670 [TBL] [Abstract][Full Text] [Related]
12. Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Conaghan P; Cohen S; Burmester G; Mysler E; Nash P; Tanaka Y; Rigby W; Patel J; Shaw T; Betts KA; Patel P; Liu J; Sun R; Fleischmann R Rheumatol Ther; 2022 Feb; 9(1):191-206. PubMed ID: 34816388 [TBL] [Abstract][Full Text] [Related]
13. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Yokoyama M; Pangan AL; Konishi Y; Meerwein S; Tanaka Y Arthritis Res Ther; 2021 Jan; 23(1):9. PubMed ID: 33407801 [TBL] [Abstract][Full Text] [Related]
15. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Haaland D; Chen L; Duan Y; Liu J; Lippe R; Wung P Rheumatol Ther; 2023 Feb; 10(1):275-292. PubMed ID: 36243812 [TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317 [TBL] [Abstract][Full Text] [Related]
18. Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Charles-Schoeman C; Giles JT; Lane NE; Choy E; Furst DE; Vencovský J; Wilson AG; Burmester GR; Coombs D; Penn SK; Khan N; Yee JB; Rahawi K; McInnes IB Rheumatol Ther; 2024 Feb; 11(1):157-175. PubMed ID: 38180720 [TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Nakashima Y; Shiomi T; Yamada E Arthritis Res Ther; 2020 Mar; 22(1):47. PubMed ID: 32164762 [TBL] [Abstract][Full Text] [Related]
20. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Hayashi S; Tachibana S; Maeda T; Yamashita M; Shirasugi I; Yamamoto Y; Yamada H; Okano T; Nishimura K; Ueda Y; Jinnno S; Saegusa J; Yamamoto W; Murata K; Fujii T; Hata K; Yoshikawa A; Ebina K; Etani Y; Yoshida N; Amuro H; Hashimoto M; Hara R; Katayama M; Okano T; Kuroda R Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 37924201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]